Custodiol versus blood cardioplegia in pediatric cardiac surgery: a randomized controlled trial.

ABSTRACT:

Background

Blood-based cardioplegia is the standard myocardial protection strategy in pediatric cardiac surgery. Custadiol (histidine-tryptophan-ketoglutarate), an alternative, may have some advantages but is potentially less effective at myocardial protection. This study aimed to test whether custadiol is not inferior to blood-based cardioplegia in pediatric cardiac surgery.

Methods

The study was designed as a randomized controlled trial with a blinded outcome assessment. All pediatric patients undergoing cardiac surgery with cardiopulmonary bypass and cardioplegia, including neonates, were eligible. Emergency surgery was excluded. The primary outcome was a composite of death within 30 days, an ICU stay longer than 5 days, or arrhythmia requiring intervention. Secondary end

SUBMITTER: Elmahrouk AF 

PROVIDER: S-EPMC10552411 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature